<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32792518</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation.</ArticleTitle><Pagination><StartPage>13741</StartPage><MedlinePgn>13741</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13741</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-70687-7</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that are considered to be on the same disease spectrum because of overlapping genetic, pathological and clinical traits. Changes in serum proteins in FTD and ALS are poorly understood, and currently no definitive biomarkers exist for diagnosing or monitoring disease progression for either disease. Here we applied quantitative discovery proteomics to analyze protein changes in FTD (N&#x2009;=&#x2009;72) and ALS (N&#x2009;=&#x2009;28) patient serum compared to controls (N&#x2009;=&#x2009;22). Twenty three proteins were significantly altered in FTD compared to controls (increased-APOL1, C3, CTSH, EIF5A, MYH2, S100A8, SUSD5, WDR1; decreased-C1S, C7, CILP2, COMP, CRTAC1, EFEMP1, FBLN1, GSN, HSPG2, IGHV1, ITIH2, PROS1, SHBG, UMOD, VASN) and 14 proteins were significantly altered in ALS compared to controls (increased-APOL1, CKM, CTSH, IGHG1, IGKC, MYH2; decreased-C7, COMP, CRTAC1, EFEMP1, FBLN1, GSN, HSPG2, SHBG). There was substantial overlap in the proteins that were altered in FTD and ALS. These results were validated using western blotting. Gene ontology tools were used to assess functional pathways potentially dysregulated in the two diseases, and calcium ion binding and innate immunity pathways were altered in both diseases. When put together, these results suggest significant overlap in pathophysiological peripheral changes in FTD and ALS. This study represents the first proteomics side-by-side comparison of serum changes in FTD and ALS, providing new insights into under-recognized perturbed pathways and an avenue for biomarker development for FTD and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katzeff</LastName><ForeName>Jared S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bright</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Kitty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Mathematics and Statistics, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kril</LastName><ForeName>Jillian J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crossett</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre and Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassiou</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Chemistry, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loy</LastName><ForeName>Clement T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Garvan Institute of Medical Research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piguet</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia. glenda.halliday@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia. glenda.halliday@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, NSW, Australia. glenda.halliday@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. glenda.halliday@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woojin Scott</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia. woojin.kim@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia. woojin.kim@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, NSW, Australia. woojin.kim@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. woojin.kim@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32792518</ArticleId><ArticleId IdType="pmc">PMC7426269</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-70687-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-70687-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences. Rev. Neurol. (Paris) 2013;169:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">24011641</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J. Neurol. Neurosurg. Psychiatry. 2010;81:639&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J. Neurol. Neurosurg. Psychiatry. 2013;84:931&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol. Neurobiol. 2018;55:7789&#x2013;7801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiani MS, et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. J. Neurol. Neurosurg. Psychiatry. 2019;90:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585261</ArticleId><ArticleId IdType="pubmed">30981993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstrom P, Andersen PM, Brannstrom T, Marklund SL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J. Neurochem. 2011;117:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">10866210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey KK, et al. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease. Clin. Proteomics. 2019;16:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472024</ArticleId><ArticleId IdType="pubmed">31019427</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19:362&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman MS, Beri J, Enders JR, Nash T. Machine learning reveals protein signatures in CSF and plasma fluids of clinical value for ALS. Sci. Rep. 2018;8:16334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218542</ArticleId><ArticleId IdType="pubmed">30397248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I, et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol. Neurodegener. 2018;13:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Systemic metabolism in frontotemporal dementia. Neurology. 2014;83:1812&#x2013;1818.</Citation><ArticleIdList><ArticleId IdType="pubmed">25305153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotarjova N, Mrozinski P, Chen H, Martosella J. Combination of affinity depletion of abundant proteins and reversed-phase fractionation in proteomic analysis of human plasma/serum. J. Chromatogr. A. 2008;1189:332&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">18154976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting L, Rad R, Gygi SP, Haas W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods. 2011;8:937&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205343</ArticleId><ArticleId IdType="pubmed">21963607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res. 2011;39:W323&#x2013;W327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125774</ArticleId><ArticleId IdType="pubmed">21609949</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. STRING v11: protein&#x2013;protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607&#x2013;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Molania R, Gagnon-Bartsch JA, Dobrovic A, Speed TP. A new normalization for Nanostring nCounter gene expression data. Nucleic Acids Res. 2019;47:6073&#x2013;6083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614807</ArticleId><ArticleId IdType="pubmed">31114909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res. Mol. Brain Res. 2002;109:128&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531522</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement. (Amst) 2016;2:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879654</ArticleId><ArticleId IdType="pubmed">27239539</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann. Clin. Transl. Neurol. 2019;6:698&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469343</ArticleId><ArticleId IdType="pubmed">31019994</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, Ludolph A, Otto M. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Rev. Proteomics. 2017;14:769&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">28799854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhof TC. Calcium control of neurotransmitter release. Cold Spring Harb. Perspect. Biol. 2012;4:a011353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249630</ArticleId><ArticleId IdType="pubmed">22068972</ArticleId></ArticleIdList></Reference><Reference><Citation>Emptage NJ, Reid CA, Fine A. Calcium stores in hippocampal synaptic boutons mediate short-term plasticity, store-operated Ca2+ entry, and spontaneous transmitter release. Neuron. 2001;29:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, et al. Extracellular calcium controls background current and neuronal excitability via an UNC79&#x2013;UNC80&#x2013;NALCN cation channel complex. Neuron. 2010;68:488&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987630</ArticleId><ArticleId IdType="pubmed">21040849</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosskreutz J, Van Den Bosch L, Keller BU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium. 2010;47:165&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">20116097</ArticleId></ArticleIdList></Reference><Reference><Citation>Palluzzi F, et al. A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia. PLoS ONE. 2017;12:e0185797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5636111</ArticleId><ArticleId IdType="pubmed">29020091</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran-Parrazal L, Charles A. Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels. Br. J. Pharmacol. 2003;140:881&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574091</ArticleId><ArticleId IdType="pubmed">14530220</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, et al. Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci. Rep. 2016;6:34904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056519</ArticleId><ArticleId IdType="pubmed">27721502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursch F, et al. Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations. Hum. Mol. Genet. 2019;28:2835&#x2013;2850.</Citation><ArticleIdList><ArticleId IdType="pubmed">31108504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, et al. C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells. 2016;34:2063&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggad D, Veriepe J, Tauffenberger A, Parker JA. TDP-43 toxicity proceeds via calcium dysregulation and necrosis in aging Caenorhabditiselegans motor neurons. J. Neurosci. 2014;34:12093&#x2013;12103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262699</ArticleId><ArticleId IdType="pubmed">25186754</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldt J, et al. Structure, regulation and related diseases of the actin-binding protein gelsolin. Expert Rev. Mol. Med. 2019;20:e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30698126</ArticleId></ArticleIdList></Reference><Reference><Citation>Piktel E, Levental I, Durnas B, Janmey PA, Bucki R. Plasma gelsolin: indicator of inflammation and its potential as a diagnostic tool and therapeutic target. Int. J. Mol. Sci. 2018;19:2516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6164782</ArticleId><ArticleId IdType="pubmed">30149613</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe H, et al. The calcium activation of gelsolin: insights from the 3A structure of the G4&#x2013;G6/actin complex. J. Mol. Biol. 2002;324:691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460571</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb. Haemost. 1991;66:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G, Perani D, Comi C. TAM receptor pathways at the crossroads of neuroinflammation and neurodegeneration. Dis Mark. 2019;2019:2387614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6766163</ArticleId><ArticleId IdType="pubmed">31636733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I, Takamura C, Kohsaka S. Fibulin-1 binds the amino-terminal head of beta-amyloid precursor protein and modulates its physiological function. J. Neurochem. 2001;76:1411&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">11238726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1) Exp. Eye Res. 2010;90:374&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896546</ArticleId><ArticleId IdType="pubmed">19799900</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, et al. Role of fibulin-3 in lung cancer: in vivo and in vitro analyses. Oncol. Rep. 2014;31:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24142183</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancaccio P, Limongelli FM, Maffulli N. Monitoring of serum enzymes in sport. Br. J. Sports Med. 2006;40:96&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492050</ArticleId><ArticleId IdType="pubmed">16431993</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Funct. Neurol. 2008;23:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">18671910</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt FM, et al. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease. Neurosci. Lett. 2014;570:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24746933</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association Calcium Hypothesis Workgroup Calcium hypothesis of Alzheimer's disease and brain aging: a framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimers Dement. 2017;13:178&#x2013;182 e117.</Citation><ArticleIdList><ArticleId IdType="pubmed">28061328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairless R, Williams SK, Diem R. Calcium-binding proteins as determinants of central nervous system neuronal vulnerability to disease. Int. J. Mol. Sci. 2019;20:2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6539299</ArticleId><ArticleId IdType="pubmed">31052285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zundorf G, Reiser G. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid. Redox Signal. 2011;14:1275&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122891</ArticleId><ArticleId IdType="pubmed">20615073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis. 2018;9:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833757</ArticleId><ArticleId IdType="pubmed">29371603</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014;14:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright F, et al. Neuroinflammation in frontotemporal dementia. Nat. Rev. Neurol. 2019;15:540&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">31324897</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lant SB, et al. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol. Appl. Neurobiol. 2014;40:686&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117616</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS) J. Neuroimmunol. 2011;230:114&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448551</ArticleId><ArticleId IdType="pubmed">20884065</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I, et al. Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies. PLoS Med. 2018;15:e1002487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760014</ArticleId><ArticleId IdType="pubmed">29315334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014;13:686&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, et al. Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 2019;137:879&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533145</ArticleId><ArticleId IdType="pubmed">30739198</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan K, et al. Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Sci. Rep. 2020;10:3640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046653</ArticleId><ArticleId IdType="pubmed">32107421</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 2012;35:369&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">22715882</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, et al. A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci. 2013;33:13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50:955&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6822103</ArticleId><ArticleId IdType="pubmed">30995509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, et al. Elevation of the terminal complement activation products C5a and C5b&#x2013;9 in ALS patient blood. J. Neuroimmunol. 2014;276:213&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">25262158</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc. Natl. Acad. Sci. U.S.A. 2014;111:E3&#x2013;E4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890900</ArticleId><ArticleId IdType="pubmed">24381160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J. Neurochem. 2011;117:528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165:921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J. Neurol. Neurosurg. Psychiatry. 2019;90:4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama DM, Norris CM. Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction. Ageing Res. Rev. 2013;12:982&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834216</ArticleId><ArticleId IdType="pubmed">23751484</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber K, Kettenmann H. Functional role of calcium signals for microglial function. Glia. 2006;54:656&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">17006894</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Rodriguez JJ, Parpura V. Calcium signalling in astroglia. Mol. Cell. Endocrinol. 2012;353:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21945602</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>